Hyperthermic intrathoracic extracorporeal chemotherapy for secondary malignant pleural disease.
cisplatin
heated chemotherapy
pleural metastasis
pleurectomy
renal failure
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
revised:
29
05
2023
received:
07
01
2023
accepted:
15
06
2023
medline:
9
8
2023
pubmed:
6
7
2023
entrez:
6
7
2023
Statut:
ppublish
Résumé
Pleural metastasis has extremely poor prognosis. Resection of pleural implants with infusion of intrathoracic hyperthermic chemotherapy may offer a survival advantage in selected patients. We evaluated the safety and efficacy of hyperthermic intrathoracic extracorporeal chemotherapy (HITEC) in patients who underwent pleurectomy/decortication (P/D) for secondary malignant pleural disease (SPD). A total of 101 patients were evaluated over 72 months, with 35 patients electing to proceed with P/D and 60 minutes of HITEC with cisplatin at 42°C. Inclusion criteria were adults 18-79 years with unilateral pleural dissemination. Exclusion criteria were patients without control of primary site, extrathoracic metastatic disease, significant comorbidities, and a history of adverse reaction to cisplatin. Median age was 56 years (36-73); 60% were women. SPD was thymoma in 13, breast cancer in 9, lung cancer in 6, colon cancer in 2, renal cell in 2, and esophageal, anal, and thymic cancers in one each. There was no operative mortality. Postoperative complications occurred in 18 patients (51%). No patient developed renal failure. Median follow-up was 24 months (4-60). The overall survival rate was 61%; 17 patients (49%) developed recurrent disease at a median of 12 months (6-36). There were no recurrences after 36 months Eleven patients (31%) died of metastatic disease at a median of 17 months (7-25). Surgical cytoreduction of SPD followed by HITEC with cisplatin was well tolerated. No patient developed cisplatin-related toxicities. Long-term follow-up is warranted to determine survival advantage and refinement of inclusion criteria.
Substances chimiques
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
604-611Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Hall B, Padussis J, Foster JM. Cytoreduction and hyperthermic intraperitoneal chemotherapy in the management of colorectal peritoneal metastasis. Surg Clin North Am. 2017;97:671-682.
Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998;14:254-261.
van der Vange N, van Goethem A, Zoetmulder F, et al. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol. 2000;26:663-668.
Mujoomdar AA, Sugarbaker DJ. Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2008;20:298-304.
Ratto GB, Civalleri D, Esposito M, et al. Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study. J Thorac Cardiovasc Surg. 1999;117:759-765.
Chang MY, Sugarbaker DJ. Innovative therapies: intraoperative intracavitary chemotherapy. Thorac Surg Clin. 2004;14:549-556.
Zhao ZY, Zhao SS, Ren M, Liu ZL, Li Z, Yang L. Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis. Oncotarget. 2017;8:100640-100647.
Richards WG, Zellos L, Bueno R, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006;24:1561-1567.
Rusch V, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol. 1994;12:1156-1163.
Aprile V, Lenzini A, Lococo F, et al. Hyperthermic intrathoracic chemotherapy for malignant pleural mesothelioma: the forefront of surgery-based multimodality treatment. J Clin Med. 2021;10:3801.
Zhou H, Wu W, Tang X, Zhou J, Shen Y. Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion: a systematic review and meta-analysis. Medicine. 2017;96:e5532.
Clive AO1, Jones HE, Bhatnagar R, Preston NJ, Maskell N. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev. 2016;8:1-5.
Kodama K, Doi O, Tatsuta M, Kuriyama K, Tateishi R. Development of postoperative intrathoracic chemothermotherapy for lung cancer with objective of improving local cure. Cancer. 1989;64:1422-1428.
Matsuzaki Y, Shibata K, Yoshioka M, et al. Intrapleural perfusion hyperthermo- chemotherapy for malignant pleural dissemination and effusion. Ann Thorac Surg. 1995;59:127-131.
Iyoda A, Yusa T, Hiroshima K, Fujisawa T. Surgical resection combined with intrathoracic hyperthermic perfusion for thymic carcinoma with an intrathoracic disseminated lesion: a case report. Anticancer Res. 1999;19:699-702.
Yellin A, Simansky DA, Paley M, Refaely Y. Hyperthermic pleural perfusion with cisplatin. early clinical experience. Cancer. 2001;92:2197-2203.
Refaely Y, Simansky DA, Paley M, Gottfried M, Yellin A. Resection and perfusion thermochemotherapy: a new approach for the treatment of thymic malignancies with pleural spread. Ann Thorac Surg. 2001;72:366-370.
Ried M, Lehle K, Neu R, et al. Assessment of cisplatin concentration and depth of penetration in human lung tissue after hyperthermic exposure. Eur J Cardiothorac Surg. 2015;47:563-566.
Markman M, Cleary S, Howell SB. Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection. Eur J Cancer Clin Oncol. 1985;21:1015-1018.
Kelsen DP, Alcock N, Young CW. Cisplatin nephrotoxicity: correlation with plasma platinum concentrations. Am J Clin Oncol. 1985;8:77-80.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
Markowiak T, Kerner N, Neu R, et al. Adequate nephroprotection reduces renal complications after hyperthermic intrathoracic chemotherapy. J Surg Oncol. 2019;120:1220-1226.
Lauk O, Patella M, Neuer T, et al. Implementing CT tumor volume and CT pleural thickness into future staging systems for malignant pleural mesothelioma. Cancer Imaging. 2021;21:48.
Hod T, Freedberg KJ, Motwani SS, et al. Acute kidney injury after cytoreductive surgery and hyperthermic intraoperative cisplatin chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2021;161:1510-1518.
Markowiak T, Larisch C, Hofmann HS, Ried M. Hyperthermic intrathoracic chemotherapy (HITHOC): narrative review of the current literature, recommendations and future studies. Ann Transl Med. 2021;9:955.
Kleontas A, Sioga A, Pandria N, et al. Clinical factors affecting the survival of patients diagnosed with non-small cell lung cancer and metastatic malignant pleural effusion, treated with hyperthermic intrathoracic chemotherapy or chemical talc pleurodesis: a monocentric, prospective, randomized trial. J Thorac Dis. 2019;11:1788-1798.
Song K, Flores RM. A narrative review of hyperthermic intrathoracic chemotherapy for advanced lung cancer. Ann Transl Med. 2021;9:958.
Yu L, Jing Y, Ma S, Li F, Zhang Y. Cytoreductive surgery combined with hyperthermic intrapleural chemotherapy to treat thymoma or thymic carcinoma with pleural dissemination. Onco Targets Ther. 2013;6:517-521.
Markowiak T, Neu R, Ansari MKA, et al. Surgical cytoreduction and HITOC for thymic malignancies with pleural dissemination. Thorac Cardiovasc Surg. 2021;69:157-164.
Aprile V, Bacchin D, Korasidis S, et al. Hypertermic intrathoracic chemotherapy (HITHOC) for thymoma: a narrative review on indications and results. Ann Transl Med. 2021;9:957.
Vannucci J, Pecoriello R, Ragusa M, Puma F. Multiple pleuropericardial implants of thymoma after videothoracoscopic resection. Interact Cardiovasc Thorac Surg. 2010;11:696-697.